Email
Hospital Circular 09/2011
Date Issued: 28 April 2011
Distribution: Public Hospitals
Subject: Highly Specialised Drugs Program
Purpose: To advise hospitals of changes to the Highly Specialised Drugs Program, effective 1 May 2011.
NEW ITEM
Levodopa with Carbidopa
| 9743T | Intestinal gel 20mg-5mg per mL, 100mL | 56 | 5 | $11,536.00 | Duodopa | AB |
Streamlined public hospital authority:
Management of advanced Parkinson disease in a patient with severe disabling motor fluctuations not adequately controlled by oral therapy. (3704)
Treatment must be commenced in a hospital-based movement disorder clinic.
Note: Patients should have adequate cognitive function to manage administration with a portable continuous infusion pump.
A positive clinical response to Duodopa administered via a temporary nasoduodenal tube should be confirmed before a permanent percutaneous endoscopic gastrostomy (PEG) tube is inserted.
Further information on the changes including the full restrictions can be found at Commonwealth/State Highly Specialised Drugs Program Guidelines website or Department of Health and Ageing website.
NEW BRANDS
Valaciclovir
| 9658N | Tablet 500mg (as hydrochloride) | 500 | 2 | $2,115.90 | Zelitrex | RE |
Maree Guyatt
Director
Integrated Care
